There are several studies about breast cancer using the CAM assay approach; the anticancer drug effects of phospholipase D2 (PLD2) and histone deacetylase (HDAC) inhibitors of the palladium complex BTC2 have been shown [85]. This evidence concerns the gene HDAC9 and breast carcinoma.